Back to search results

Rural Community Peer Partnerships for Methamphetamine-Associated Heart Failure

This study, called PEER-Heart, is looking at ways to improve how people in rural areas who use methamphetamine get screened for and treated for heart failure related to methamphetamine use. You might be able to join if you are 18 or older, have used methamphetamine in the last year and past 30 days, and don't have a current heart failure diagnosis. You would also need to screen positive for potential methamphetamine-associated heart failure (MAHF) based on certain blood tests (BNP levels) or heart measurements (QRS width). The study is comparing two approaches: one where a peer helps you get referred to a local doctor, and another where a peer helps you get a virtual appointment with a heart specialist. The main goal is to see if these approaches help people connect with heart care within two months. The study aims to enroll 200 people and its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific intervention. It plans to enroll 200 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for linkage to cardiology care, measured at 2 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06461962

Rural Community Peer Partnerships for Improving Methamphetamine-Associated Heart Failure Screening and Engagement

Recruiting
NAAges 18+InterventionalScreening
Oregon Health and Science University
~200 participants
Updated 2025-03-21 on ClinicalTrials.gov
What's tested:Treatment as UsualTelehealth-Cardiology

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Linkage to cardiology care
Measured over 2 months

Conditions

Methamphetamine Use
Heart Failure

Explore related trials

Heart FailureMethamphetamine UseNPPB wt Allele

NCT06461962

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Oregon Health & Science University

    Portland, Oregonstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Brian Chan, MD, MPH · PRINCIPAL_INVESTIGATOR · Oregon Health and Science University

Who to contact

Brian Chan, MD, MPH
[email protected]
503-494-2010
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient-defined regular use of methamphetamine in the last year
Any methamphetamine use in the past 30 days
Age 18 years or older
No client-reported diagnosis of heart failure
Able to communicate in English
Screen positive for potential methamphetamine-associated heart failure (MAHF) defined as B type natriuretic peptide (BNP) ≥50 pg/ml, or QRS width ≥120ms, or presence of any clinical heart failure symptoms

Exclusion

Self-reported engagement in medical care for heart failure in past 6 months.
Actively taking medications for heart failure.

What this trial measures

  • Linkage to cardiology care2 months

    Proportion of participants who are engaged in cardiac care at 2 months after screening.